Press Releases Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
3 ^USD	+1.35%		+6.01%	-5.66%

Mar. 07	Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	Apr. 18	GL
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	Mar. 20	GL
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	Mar. 07	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	AQ
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	GL
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	AQ
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	GL
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	AQ
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	GL
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	AQ
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November	Nov. 20	GL
Lumos: Q3 Earnings Snapshot	Nov. 07	AQ
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates	Nov. 07	GL
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints	Nov. 07	GL
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints	Nov. 07	AQ
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting	23-09-26	GL
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting	23-09-26	AQ
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting	23-09-14	GL
Lumos Pharma Announces Participation in Investor Conferences in September	23-09-07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Press Releases

Filters